Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,132,096

« Back to Dashboard
Patent 9,132,096 protects ZOHYDRO ER and is included in one NDA. There has been one Paragraph IV challenge on Zohydro ER. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has two patent family members in two countries.

Summary for Patent: 9,132,096

Title:Abuse resistant pharmaceutical compositions
Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.
Inventor(s): Rekhi; Gurvinder Singh (Suwanee, GA), Sidwell; Richard (Cumming, GA)
Assignee: Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:14/484,761
Patent Claim Types:
see list of patent claims
Composition; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 115th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pernix Ireland Pain
hydrocodone bitartrate
CAPSULE, EXTENDED RELEASE;ORAL202880-001Oct 25, 2013RXYesYes9,132,096► subscribeY
Pernix Ireland Pain
hydrocodone bitartrate
CAPSULE, EXTENDED RELEASE;ORAL202880-002Oct 25, 2013RXYesNo9,132,096► subscribeY
Pernix Ireland Pain
hydrocodone bitartrate
CAPSULE, EXTENDED RELEASE;ORAL202880-003Oct 25, 2013RXYesNo9,132,096► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,132,096

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2870380► subscribe
World Intellectual Property Organization (WIPO)2016038584► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.